1. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
- Author
-
McCormick J and Tubman R
- Subjects
- Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antiviral Agents therapeutic use, Cohort Studies, Cost-Benefit Analysis, Female, Humans, Incidence, Infant, Infant, Newborn, Intensive Care Units, Neonatal economics, Ireland epidemiology, Male, Medical Audit, Palivizumab, Probability, Respiratory Syncytial Virus Infections epidemiology, Retrospective Studies, Risk, Antibodies, Monoclonal economics, Antiviral Agents economics, Patient Readmission economics, Patient Readmission statistics & numerical data, Respiratory Syncytial Virus Infections prevention & control
- Abstract
We evaluated the incidence of readmission with respiratory syncytial virus (RSV) infection among the graduates of a regional Neonatal Intensive Care Unit (NICU), and characterized those who were rehospitalized. These data were used as a predictive tool to estimate the number of babies likely to suffer readmission with RSV for the year 2000 cohort. Using the published efficacies of palivizumab, the costs and benefits of protecting this cohort were assessed. Retrospective analysis of 2,507 NICU inpatient records from January 1, 1994-December 31, 1999 from the Royal Maternity Hospital, Belfast, were compared with data on positive RSV samples from 1,790 patients between January 1, 1995-December 31, 1999 from the Northern Ireland Regional Virus Laboratory. The analysis yielded 136 (7.6%) ex-NICU patients among the positive RSV samples over this 5-year period. Characteristic seasonal peaks of RSV infection with interseasonal variability were observed. Of those readmitted, 86.9% were hospitalized with RSV before their first birthday. A calculated readmission rate of 5.4% for all NICU graduates, and 6.4% for those
- Published
- 2002
- Full Text
- View/download PDF